๐”– Bobbio Scriptorium
โœฆ   LIBER   โœฆ

Pharmacokinetics of pantoprazole following single intravenous and oral administration to healthy male subjects

โœ Scribed by M. A. Pue; J. Laroche; I. Meineke; C. de Mey

Publisher
Springer
Year
1993
Tongue
English
Weight
415 KB
Volume
44
Category
Article
ISSN
0031-6970

No coin nor oath required. For personal study only.

๐Ÿ“œ SIMILAR VOLUMES

Pharmacokinetics of ketotiffn after oral
Pharmacokinetics of ketotiffn after oral administration to healthy male subjects
โœ Dr A. Grahnรฉn; A. Lรถnnebo; O. Beck; S-ร… Eckernรคs; B. Dahlstrรถm; B. Lindstrรถm ๐Ÿ“‚ Article ๐Ÿ“… 1992 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 406 KB ๐Ÿ‘ 2 views

## Abstract The pharmacokinetics of 2 mg ketotifen from four different oral dosage forms were examined in two randomized, balanced crossโ€over studies. Forty healthy male subjects participated. Each of 20 subjects received two capsule formulations and each of the other 20 subjects received two syrup

Pharmacokinetics of dolasetron following
Pharmacokinetics of dolasetron following single- and multiple-dose intravenous administration to normal male subjects
โœ Ajit Shah; Robert Lanman; Vijay Bhargava; Scott Weir; William Hahne ๐Ÿ“‚ Article ๐Ÿ“… 1995 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 561 KB

Dolasetron, AnzemetTM, a 5-hydroxytryptamine receptor antagonist, is under investigation as an antiemetic agent. The keto-reduced metabolite of dolasetron has been identified in human plasma and is probably responsible for the majority of the antiemetic activity. This study evaluated the pharmacokin

Human dolasetron pharmacokinetics: I. Di
Human dolasetron pharmacokinetics: I. Disposition following single-dose intravenous administration to normal male subjects
โœ Harold Boxenbaum; Todd Gillespie; Kathleen Heck; William Hahne ๐Ÿ“‚ Article ๐Ÿ“… 1992 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 471 KB ๐Ÿ‘ 2 views

Dolasetron is a 5-hydroxytryptamine antagonist active at type 111 receptors; it is presently undergoing clinical evaluation for the reduction/prevention of cancer chemotherapyinduced nausea and vomiting. Following intravenous administration to healthy male subjects of doses ranging from 0.6 to 5 mg

Human dolasetron pharmacokinetics: II Ab
Human dolasetron pharmacokinetics: II Absorption and disposition following single-dose oral administration to normal male subjects
โœ Harold Boxenbaum; Todd Gillespie; Kathleen Heck; William Hahne ๐Ÿ“‚ Article ๐Ÿ“… 1993 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 485 KB ๐Ÿ‘ 2 views

## Abstract Dolasetron is a 5โ€hydroxytryptamine antagonist active at type III receptors; it is presently undergoing clinical evaluation for the reduction/prevention of cancer chemotherapyinduced nausea and vomiting. A previous study demonstrated that following intravenous administration to healthy